The Latest Research Progress of Selinexor in the Treatment of Non-Hodgkin Lymphoma --Review.
10.19746/j.cnki.issn.1009-2137.2023.01.046
- Author:
Xin-Yu TANG
1
;
Yan WANG
2
;
Rui-Rong XU
3
Author Information
1. The First Clinical College of Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong Province, China.
2. Department of Hematology, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong Province, China,E-mail：yaner_wang@sina.com.
3. Department of Hematology, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong Province, China.
- Publication Type:Journal Article
- Keywords:
XPO1;
mechanism;
non-Hodgkin lymphoma;
selinexor
- MeSH:
Humans;
Lymphoma, Non-Hodgkin/drug therapy*;
Active Transport, Cell Nucleus;
Hydrazines/pharmacology*;
Triazoles/therapeutic use*;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
- From:
Journal of Experimental Hematology
2023;31(1):292-296
- CountryChina
- Language:Chinese
-
Abstract:
Non-Hodgkin lymphoma (NHL) is a common lymphoid hematological malignancy, the treatment and prognosis of NHL have always been the focus of clinical attention. Chemotherapy is the main first-line treatment, but there is still no effective treatment for patients with poor response to chemotherapy, recurrence or progression within a short period of time after treatment, and new and effective drugs need to be developed clinically. As the only clinically validated oral selective inhibitor of nuclear export (SINE), Selinexor has been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma and multiple myeloma, clinical attempts are being made to apply it to the treatment of other hematological malignancies.This article reviews the anti-tumor mechanism of Selinexor and the latest research progress in its application in NHL, and provides ideas for a more diverse, standardized and effective applications of Selinexor in NHL.
